Role of clonal expansion in HIV-1 persistence
- Institution
- Yale University, CT
- Principal investigator
- Ya-Chi Ho
- Funding
- $847K
- Duration
- 2018–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Despite effective antiretroviral therapy (ART), HIV-1 persists in memory CD4+ T cells as the major barrier to cure. ART inhibits viral enzyme function but does not kill infected cells. Around 12 million HIV-1-infected CD4+ T cells establish the HIV-1 reservoir. HIV-1-infected cells survive viral cytopathic effects, evade cytotoxic CD8+ T cell killing, and persist over time. What is even worse, these HIV-1-infected cells proliferate: more than 50% of the HIV-1 reservoir undergo clonal expansion through antigen stimulation, homeostatic cytokine stimulation, or HIV- 1 integration site-driven proliferation. Understanding mechanisms of the clonal expansion of HIV-1-infected cells is a top priority to stop the proliferation of HIV-1-infected cells and guide the design of HIV-1 cure. However, understanding HIV-1 persistence in people living with HIV-1 is extremely challenging. First, CD4+ T cells are highly heterogeneous, having different T cell polarization (such as Th1, Th2, Th17, and T reg), memory differentiation (such as naïve, central memory, effector memory, and effector), activation states, exhaustion states, proliferation capacity, and antigen specificity. Second, HIV-1-infected cells harboring inducible HIV-1 are extremely rare in HIV-1-infected individuals, accounting for ~1–100/million CD4+ T cells (<0.01%) in the peripheral blood. Third, there is no cellular marker that can precisely identify HIV-1-infected cells for single-cell profiling. We recently used a cutting-edge single-cell multi-omic profiling method called ECCITEseq to decipher the heterogeneity of immune cell types and capture the rare HIV-1-infected cells. This single-cell multi-omic method allows us to capture single-cell transcriptome at the genome-wide level, profile more than 100 cellular protein markers, detect HIV-1 RNA+ cells, and capture T cell proliferation dynamics by T cell receptor (TCR) sequencing, all within the same single cell. This allows us to determine immune programs, clonal expansion dynamics, and cell markers for HIV-1 RNA+ cells for high-dimensional, multi-omic, and genome-wide understanding of HIV-1 persistence without ex vivo stimulation. Using advanced single-cell multi-omic approach, we tracked the clonally expanding CD4+ T cells between different anatomical locations in the body. In addition, we identified a pro-survival cellular factor that is upregulated in HIV-1-infected cells and may promote the proliferation of HIV-1-infecte cells. We hypothesize that HIV-1-infected CD4+ T cells traffic to different tissue compartments and persist under cytokine cues in the tissue compartment. We further hypothesize that HIV-1- infected cells can resist viral cytopathic effect by upregulating this pro-survival cellular factor. Our goal is to track the clonal expansion dynamics of HIV-1+ cells over space and time (Aim 1) and decipher how HIV-1-infected cells survive viral cytopathic effect and proliferate (Aim 2). Overall, we will provide an unprecedented understanding of HIV-1 reservoir regarding mechanisms of HIV-1 persistence and clonal expansion dynamics of HIV-1-infected cells at the single cell level. We will identify therapeutic targets and guide HIV-1 eradication strategies.
LOADING MOONBASE SCORE
Questions for Yale University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Yale UniversityNot yet scored
Understanding HIV-1 persistence and HIV-1-induced inflammation in tissues
Ya-Chi Ho · $847K · 2024–2029
- NIH · Yale UniversityNot yet scored
Understanding HIV-1 persistence in cytotoxic CD4+ T lymphocytes at the single cell level
Ya-Chi Ho · $840K · 2023–2027
- NIH · Yale UniversityNot yet scored
M-SCORCH: Methamphetamine use disorder data generation center for Single Cell Opioid Responses in the Context of HIV
Ya-Chi Ho · $1.9M · 2021–2026